A novel coronavirus has been identified to be associated with the newly outbreak of severe acute respiratory syndrome (SARS). To date 12 whole genome sequences from various samples are available in public-domain database. Spike protein of coronavirus is considered to be the major antigen and contains many potential antigenicity domains. The relatively low mutation rate in spike protein provides high opportunity for effective vaccine development. Since inactivated or attenuated coronavirus holds some potential limitations and risks to prepare and to inoculate, the current best hope for protection is to combine a protein vaccine (i.e., a purified SARS coronavirus spike protein) with a “vectored” vaccine, consisting of a plasmid or a harmless virus, such as recombinant adenovirus which has been genetically engineered to produce coronavirus spike protein.